

GLAXOSMITHKLINE PLC
Form 6-K
September 27, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 27 September 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction

Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Walmsley will receive a cash payment of £154,279.74 less applicable tax withholding in respect of 10,075.600 notional Ordinary Shares.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.314	10,075.600
- d) Aggregated information

n/a (single transaction)
- e) Date of the transaction

2018-09-23
- f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Vaccines

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Connor will receive
- b) Nature of the transaction a cash payment of £123,438.19 less applicable tax withholding in respect of 8,060.480 notional Ordinary Shares.
- c) Price(s) and volume(s) Price(s) Volume(s)
£15.314 8,060.480
- Aggregated information
- d) n/a (single transaction)
- Aggregated volume Price
- e) Date of the transaction 2018-09-23
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £123,438.19 less applicable tax withholding in respect of 8,060.480 notional Ordinary Shares.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.314	8,060.480

Aggregated information

d)

n/a (single transaction)

Aggregated volume Price

e) Date of the transaction

2018-09-23

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Ms C Thomas

b) Position/status

SVP, Human Resources

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction

Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £123,438.19 less applicable

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

tax withholding in respect of
8,060.480 notional Ordinary
Shares.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.314	8,060.480
Aggregated information		
d) Aggregated volume	n/a (single transaction)	
e) Date of the transaction	2018-09-23	
f) Place of the transaction	n/a	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GlaxoSmithKline plc
(Registrant)

Date: September 27, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorized Signatory for and on
behalf of GlaxoSmithKline plc